2019 Cannabis Business Award's Publication of the Year |
WEDNESDAY, OCTOBER 8, 2025 |
FMCPG HAS BEEN SERVING AND REPRESENTING THE CANNABIS PHYSICIAN COMMUNITY
SINCE 2020 |
THE "FLORIDA MEDICAL CANNABIS PHYSICIAN GROUP" (FMCPG) FOR ALL
"MEDICAL MARIJUANA DOCTORS" AND "MMTC DIRECTORS ONLY " DISCUSS AND UPDATE THE LEGISLATIVE PRIORITIES FOR
2025/2026
REVIEW OF THE OMMU AND CHANGES TO THE DOCTOR'S AND PATIENT INPUT PORTALS ON THE OMMU WEBSITE.
DOCTORS WITHIN OUR GROUP WILL DISCUSS HOW THEY HAVE BEEN WORKING AROUND SOME OF THE CHANGES
REF'S ISSUES AND SOLUTIONS
TIME TO RENEW YOUR MEMBER IN FMCPG
CLICK HERE FOR THE MEMBERSHIP FORM USE THIS LINK TO REGISTER FOR THE NEXT MEETING - WEDNESDAY, OCTOBER 8, 2025 CLICK ON LINK BELOW |
MEDICAL CANNABIS PHYSICIAN PROMOTION PACKAGE BY CANNABIS NEWS FLORIDA
ARTICLE: Physician will contribute an article of 350 words**. This article will appear in the Cannabis News Florida e-newsletter for one month (4 weeks).
E-MAIL BLAST: Cannabis News Florida will send out one e-mail blast promoting the Physician to the other physicians in three zip code areas or one city to be determined by the Physician. The Physician will supply the information for the email blast. The Article above can be used in the e-mail blast.
The cost of this program is ONLY $500 AND INCLUDES A ONE YEAR MEMBERSHIP IN THE FMCPG **Cannabis News Florida will assign a writer for a telephone interview with the Physician and create the article to be published. Physician shall have the right to review and approve the article before publication for an additional cost of $100.
IF YOU ARE INTERESTED, PLEASE EMAIL ME AT CHARLES@CANNABISNEWSFLORIDA.COM OR CALL MY CELL AT 954-605-4785 |
NEWS FROM THE PAST WEEK RELATING TO THE BUSINESS OF
MMTC'S IN FLORIDA Click on Company Logo to be Transferred to Web Site |
Trulieve Rewards
Trulieve Rewards is a customer rewards program offering patients and customers in participating states an easy platform to earn points on every purchase at Trulieve dispensaries. We've revamped and refreshed our old cannabis loyalty program to reward cannabis enthusiasts loyal to Trulieve with savings, perks, and points every time they shop for cannabis products JOIN NOW |
The Cannabist Company Holdings Inc. Announces Co-Founder Michael Abbott’s Resignation from Board
CHELMSFORD, Mass.-Oct. 6, 2025– The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced today that Michael Abbott resigned as a director of the Board of Directors (the “Board”) of the Company, effective October 3, 2025, in order to pursue other personal and professional commitments. Abbott co-founded the Company as Columbia Care in 2012 and served as Executive Chairman of the Board until 2023, and, since then, as Chair of the Board. David Hart, Chief Executive Officer and Director, commented, “On behalf of the Board and the management team, I thank Michael for his innumerable contributions to the Company since its founding and for his unwavering support of the Company across the years. We wish him all the best with future endeavors.”
READ MORE |
Curaleaf and The Baldwin Fund Partner to Raise Funds for Breast Cancer Research This October
Curaleaf celebrates six years of its national at-register donation program for Breast Cancer Action Month
All contributions benefit The Carol M. Baldwin Breast Cancer Research Fund of CNY, also known as The Baldwin Fun
STAMFORD, Conn., Oct. 1, 2025 — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, is proud to announce its continued Breast Cancer Action Month (BCAM) initiative, this year in partnership with Carol M. Baldwin Breast Cancer Research Fund of CNY, also known as The Baldwin Fund. Throughout October, Curaleaf customers at the majority of the company’s retail locations are invited to “Round Up for Research” at checkout, with proceeds supporting lifesaving breast cancer research at Upstate Medical University in Syracuse, New York.
This year’s partnership will allow Curaleaf to scale its impact nationwide, uniting customers and communities around a shared goal of funding breakthrough research and honoring those who have faced breast cancer. For more than 20 years, The Baldwin Fund has raised over $13 million to advance breast cancer research and patient care, building on founder Carol M. Baldwin’s mantra: “Together We Will Find a Cure.” Today, the Fund is embarking on a bold $50 million campaign to help the Upstate Cancer Center achieve National Cancer Institute (NCI) designation, the gold standard for innovative cancer programs.
READ MORE |
Green Thumb Expands Pennsylvania Retail Footprint with RISE Dispensary Lebanon
Conveniently located near Downtown Lebanon off Route 422, RISE Dispensary Lebanon is located at 1600 W Cumberland St. Lebanon, PA 17042.
RISE Dispensary Lebanon will host a grand opening celebration for its patients and the community on October 3.
Continuing with RISE’s new store opening tradition, profits from the RISE Dispensary Lebanon grand opening will benefit local non-profit Making A Difference of Lebanon, PA.
CHICAGO and VANCOUVER, British Columbia, Sept. 30, 2025 — RISE Dispensaries, a rapidly growing cannabis retail chain owned by Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), today announced its latest Pennsylvania location, RISE Dispensary Lebanon. Located at 1600 W Cumberland St. conveniently near Downtown Lebanon off Route 422, RISE Dispensary Lebanon is the Company’s 19th retail location in Pennsylvania and 108th nationwide.
RISE Dispensary Lebanon brings Pennsylvania patients best-in-class products and convenient services, such as online pre-order for pick up. RISE Dispensary Lebanon is open 9 a.m. until 8 p.m. Monday through Saturday and 10 a.m. until 6 p.m. on Sundays, offering a variety of products from Green Thumb’s portfolio, including RYTHM premium flower, full-spectrum vapes and concentrates, Good Green flower, &Shine troches and Doctor Solomon’s topicals.
READ MORE
|
Red White & Bloom Files 2025 Interim Financial Statements
TORONTO, Oct. 03, 2025 — Red White & Bloom Brands Inc. (CSE: RWB) (“RWB” or the “Company”) announces that it has completed and filed its interim financial statements for the periods ended March 31, 2025 and June 30, 2025, and the related management’s discussion and analysis and CEO and CFO certificates. Copies of the noted documents are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.
With the filing of these documents, the Company has now brought its continuous disclosure record up to date. The failure-to-file cease trade order (the “FFCTO”) issued by the British Columbia Securities Commission on July 3, 2025, has been revoked. Trading in the Company’s securities on the Canadian Securities Exchange is expected to resume on October 3, 2025.
READ MORE |
Verano Secures US $75,000,000 Revolving Credit Facility
Company draws US $50,000,000 to retire US $50,000,000 of its existing senior secured credit facility
CHICAGO, Oct. 01, 2025 — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the closing of a credit agreement agented by Chicago Atlantic Admin, LLC, with participation from a regional bank, to provide the Company a revolving credit facility (the “Revolver”) of US $75,000,000. Upon closing the Revolver, the Company drew US $50,000,000 to pay down US $50,000,000 of higher interest rate debt from its existing senior secured credit facility without incurring any prepayment penalty, with the remaining US $25,000,000 being available to fund strategic initiatives.
The Revolver, which is secured by selected real estate, provides Verano a range of benefits including lower cost debt, payoff and redraw flexibility, and optionality to have certain real estate released as collateral under the Revolver.
“Closing the $75 million revolving credit facility demonstrates our focus on fortifying the balance sheet, accessing lower cost debt, and leveraging our owned real estate to strengthen our foundation and position Verano to take advantage of future opportunities,” said George Archos, Verano founder and Chief Executive Officer. “We view today’s closing as another important step forward in executing our capital and finance strategy that will benefit Verano, our employees and shareholders in the long-term, and we look forward to making continued progress as we explore opportunities in the market.”
READ MORE |
Verano Provides Update on the Canadian Postal Strike, the Company’s Special Meeting Materials and Voting Instructions
CHICAGO, Oct. 06, 2025 — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, is advising shareholders that due to the ongoing Canadian postal strike, the Company’s meeting materials (the “Meeting Materials”) for the Company’s upcoming special meeting to be held on October 27, 2025 at 9:30 a.m. (CDT), may not be delivered to all shareholders prior to the meeting date.
The Meeting Materials may be accessed on the Company’s SEDAR+ profile at www.sedarplus.ca, on its EDGAR profile at www.sec.gov and are also available on its website at https://investors.verano.com/events-presentations/events.
The Company is working to mail the Meeting Materials in the normal course, but due to the postal strike in Canada, there can be no assurance that the Meeting Materials will be delivered to all shareholders’ respective addresses prior to the Meeting.
In light of the Canadian postal strike, shareholders should cast their vote online and not send their proxy by mail. In the event a shareholder received the Meeting Materials and mailed their vote, the Company asks that shareholders recast their votes online to ensure their voting instructions are received in a timely manner. Notwithstanding the proxy cut-off time stated in the Meeting Materials, the Company will accept votes submitted by proxy until at least 9:30 a.m. Central Time on October 24, 2025. Beneficial shareholders should submit their votes at least 24 hours before the proxy cut-off time.
READ MORE |
The ongoing cannabis worker strikes in Michigan and Pennsylvania represent the longest work stoppages in U.S. cannabis history, surpassing a previous 13-day record from 2023. |
In Michigan, four employees at Exclusive Brands have been on strike since August 28 over the company’s refusal to recognize the results of a union election. Despite the operator’s social equity branding, the company remains open, with claims of over 200 workers on the job.
In Pennsylvania, eight unionized workers at Gren Thumb’s RISE dispensary in York have been on strike since September 1, demanding a starting wage of $18/hour (up from $16-17.65) and better benefits after stalled contract talks.
It’s hard not to sympathize with the plight of entry-level cannabis workers. Paying for their participation in an industry they are devoted to with low wages and little job security. But these workers are also up against powerful industry forces. The two settings of Michigan and Pennsylvania could not be more different in key ways that impact the strikers’ negotiating power.
Michigan workers are battling state conditions as much as their employer. Wide-open licensing has led to an explosion in cultivation capacity and the number of stores. Michigan’s 840 dispensaries represent 11.1 stores per 100k adults, higher than any other top ten market except Colorado. Sales per dispensary average only $4M per year, a level that is suboptimal for operating profitability. Market pricing reflects this overcapacity. The average retail price for September 2025 is less than $1,000 per pound. The bottom line is that Michigan operators have limited options; many are struggling to make ends meet. And things might be getting worse; the Michigan legislature has just passed a 24% wholesale tax that, if not reversed, is likely to reduce cross-border traffic to Michigan stores and drive sales back to the illicit market. MSOs are generally absent from the market, and only around 2% of retail stores are now operated by MSOs
Things could not be more different in Pennsylvania. PA is a tightly regulated medical state with only 191 dispensaries, averaging around $10 million in revenues. Retail prices have decreased slightly, but they remain attractive at around $3,400 per pound. MSOs are more dominant IN PA than in any other state we can point to, with over 81% of the stores operated by MSOs. The state is doing well and looks to gain another bump in revenues and profits if plans to go adult rec materialize. Workers here are striking against power rather than economics. Big MJSOs don’t want to give concessions in PA because they fear they will face similar demands in all their other markets. But it’s not that they couldn’t afford to raise workers’ wages a bit; it’s more that they don’t feel that they need to.
The cannabis industry is in a strange situation. Their customers are increasingly saying that their budgets are strained, and increasingly, they are hearing that from their own employees. |
For More Analysis View This Week's Viridian Chart of the Week About Viridian Capital Advisors
Since launching in 2014, Viridian Capital Advisors has become one of the most respected and experienced advisory and M&A firms specializing in the cannabis industry. We provide a wide range of services, including:
Strategic Advisory Consulting: Including valuation, financial modeling, restructuring and fairness opinions. Mergers & Acquisitions: Transaction advisory and execution. Capital Raises: Including debt and equity. Many of our assignments begin with a basic question: "What should I do now?" Raise capital to expand? What kind of capital is most appropriate?
Acquire another company? What are the advantages and pitfalls? Sell my company? What valuations can i achieve? What transaction structures are possible?
Put our experience, data and depth of senior talent behind your next transaction.
Contact
Scott Greiper
CEO
Viridian Capital Advisors, LLC
646.330.0704
sgreiper@viridianca.com
Frank Colombo
Managing Director
Viridian Capital Advisors, LLC
914.523.4730
fcolombo@viridianca.com
|
NATIONAL AND INTERNATIONAL NEWS |
Cleveland Clinic Study Demonstrates Safety, Effectiveness of Ketamine for Chronic Pain
Low-dose infusions show significant improvement for patients, in one of the largest studies of its kind
October 6, 2025 – Low-dose ketamine infusions are both safe and significantly effective for patients with chronic pain, according to one of the largest real-world studies of its kind published today in Regional Anesthesia & Pain Medicine.
Led by researchers at Cleveland Clinic’s Neurological and Primary Care Institutes, the study analyzed data from over 1,000 patients, providing crucial evidence for this emerging treatment approach.
“We know millions of Americans are suffering from chronic pain and this research addresses critical gaps in pain management and shows a significant step forward in improving care for those patients who have otherwise exhausted all other treatment options,” said Pavan Tankha, D.O., medical director of Comprehensive Pain Recovery in Cleveland Clinic’s Neurological Institute. “The findings of the research represent a meaningful step toward improved quality of life and may accelerate access to this treatment option for patients all over the country.”
The retrospective study followed 1,034 patients through a standardized ketamine infusion protocol – 0.5 mg/kg over 40 minutes for five consecutive days – and demonstrated an 86.1% adherence rate, underscoring the feasibility of outpatient administration.
READ MORE |
Tilray, a Global Leader in Medical Cannabis, Announces Expansion of Premium Craft Cannabis Production at its Advanced EU-GMP Facility in Germany; Tilray Medical Enhances Tilray Craft Cannabis Portfolio with New Patient-Centered Offerings
NEUMÜNSTER, Germany, Sept. 30, 2025 — Tilray Medical a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare today announced the expansion of its Tilray Craft portfolio in Germany with five new cannabis flower products produced in Germany at Tilray’s EU‑GMP certified facility in Neumünster as part of the BfArM in‑country cultivation program. The additions reflect Tilray’s ongoing commitment to providing physicians and pharmacies with a diverse range of quality, EU‑GMP certified medical cannabis options for eligible patients.
Rajnish Ohri, Managing Director International at Tilray Brands, commented, “The expansion of our Tilray Craft premium cannabis flower range demonstrates our commitment to patient care in Germany. As a global leader in medical cannabis, supported by our advanced EU-GMP facility in Germany, Tilray continuously introduces new genetics bred to pharmaceutical standards at Neumünster. This approach enables us to provide reliable, patient-focused medical cannabis options. Our priority remains delivering consistent, quality solutions to physicians and pharmacies, always placing patients’ needs first.”
READ MORE |
Optimi Health’s Psilocybin Capsules Selected for Medibank Insurance Program
Australia’s largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSD
Vancouver, British Columbia- October 6, 2025 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion in Medibank’s psychotherapy program, an AUD $10 million insurance-backed initiative that has now been expanded to cover Treatment-Resistant Depression (“TRD“).
Medibank, Australia’s largest private health insurer with approximately 4.2 million customers, has expanded its psychotherapy program to reimburse psilocybin-assisted therapy for patients with TRD, following its earlier funding of an MDMA-assisted therapy for Post-Traumatic Stress Disorder (“PTSD“).
For this program, Emyria Limited, through its wholly owned Empax Centre located in Perth, Western Australia, is responsible for delivery of clinical services, and selected Optimi’s psilocybin capsules for inclusion in the program through Optimi’s exclusive distributor Mind Medicine Australia.
READ MORE |
BELOW ARE THE LINKS TO THE DIRECTORY OF FLORIDA CANNABIS DOCTORS AND
DISPENSARIES IN THE STATE OF FLORIDA |
QUALIFIED PATIENTS
OVER 926,000
AND 734 DISPENSING LOCATIONS |
LATEST OMMU REPORTS FROM OFFICE OF MEDICAL MARIJUANA USE IN THE STATE OF FLORIDA Highlights from
OCTOBER 3, 2025 Report BY THE NUMBERS
Qualified Patients: (Active ID Card)
OCT 03 2025 926,467
SEPT 26 2025 925,084
SEPT 19 2025 924,797
SEPT 12 2025 924,473
SEPT 05 2025 923,918
Patients Last Week: 1,384
Qualified Ordering Physicians: 2,435
New Doctors Last Week: 4 Reporting Period: SEPT 26 - OCT 2, 2025
Amount of Medical Marijuana Dispensed - (mgs THC) 390,622,320
Amount of Low-THC Cannabis Dispensed - (mgs CBD) 0
Amount of Marijuana in a From for Smoking (oz) 135,280.024
Approved Dispensing Locations: 734
ADDED LAST WEEK 1 EDEN - SARASOTA |
UPCOMING MEETING AND CONFERENCES LOOK FOR IN FUTURE ISSUES |
ADVERTISEMENT OPPORTUNITIES
If your goal is to get your business in front of the right people in the cannabis industry or you want to be an integral part of this new and exciting business opportunity, then you need to join with Cannabis News Florida as we help to establish cannabis as a major part of the economy in Florida. Cannabis News Florida is an online publication focusing on both local and national news from leading authorities about the medical and business developments in the medical cannabis industry covering the entire state of Florida.
Join the Cannabis News Florida force online and in print. We offer several marketing options to fit all budgets:
· MMTC PROMOS LISTED IN EACH E-NEWSLETTER
• Directory Listing
• Banner Ads
• Ad Space in the Newspaper
• Feature Articles
• Weekly Newsletters
For further information or to make your ad reservation, please call:561-368-6950 / 954-605-4785 cell charles@cannabisnewsflorida.com
|
|
|